Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nosocomial transmission in a monkeypox virus clade Ib outbreak, Ireland, August to October 2025.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025
Same author

Mpox due to monkeypox virus clade Ia infection detected outside of Africa: a case study.

Communications medicine·2025
Same author

Associations of Self-Rated Deficits in Executive Function with Lower Urinary Tract Symptoms, Adaptive Behaviors, and Bladder Health among Women.

Journal of women's health (2002)·2025
Same author

Evaluation of Bladder Dysfunction Outcomes Among Standardized Bladder Shapes in Children With Spina Bifida.

Neurourology and urodynamics·2025
Same author

Comparison of open and robot-assisted repair for ureteropelvic junction obstruction: Outcomes and direct costs from a single-institution.

Journal of pediatric urology·2025
Same author

Associations between type III interferons, obesity and clinical severity of COVID-19.

Frontiers in immunology·2025
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Methylphenidate for giggle incontinence.

Amanda K Berry1, Stephen Zderic, Michael Carr

  • 1Division of Urology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.

The Journal of Urology
|August 22, 2009
PubMed
Summary
This summary is machine-generated.

Giggle incontinence, or enuresis risoria, is involuntary bladder emptying triggered by laughter. Methylphenidate effectively treated this condition in 75% of children studied, offering a viable solution for this rare form of incontinence.

More Related Videos

Gastrointestinal Motility Monitor (GIMM)
08:15

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Related Experiment Videos

Last Updated: Jun 20, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Gastrointestinal Motility Monitor (GIMM)
08:15

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Area of Science:

  • Pediatric Urology
  • Neurology
  • Continence Disorders

Background:

  • Giggle incontinence (enuresis risoria) is a socially distressing condition involving complete bladder emptying during laughter.
  • The exact cause remains unknown, with a potential link to cataplexy suggested.

Purpose of the Study:

  • To retrospectively evaluate the efficacy of methylphenidate for treating giggle incontinence in children.
  • To assess the impact of methylphenidate on wetting frequency in pediatric patients.

Main Methods:

  • Charts of 20 children diagnosed with giggle incontinence (without urgency or urge incontinence) were reviewed.
  • Patients meeting criteria were offered a methylphenidate trial, with wetting frequency assessed pre- and during treatment.

Main Results:

  • 15 out of 20 patients (75%) opted for a methylphenidate trial.
  • 12 out of 15 patients (80%) experienced prompt and complete cessation of wetting.
  • Treatment duration varied from 2 months to over 3 years.

Conclusions:

  • Methylphenidate presents a viable treatment option for giggle incontinence in children.
  • Not all families accepted methylphenidate treatment, indicating a need for further research and alternative options.